Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 13/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688394 | 0.91 | NR1H4 (0.48) | ACMSDKMT2AMEN1POLBADORA1 | |
| SCHEMBL32688064 | 0.89 | ACMSD (0.52) | ACMSDKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL20340172 | 0.89 | ACMSD (0.61) | ACMSDKMT2AMEN1POLBADORA1 | |
| SCHEMBL32688164 | 0.88 | KMT2A (0.47) | ACMSDKMT2AMEN1POLBNR1H4 | |
| SCHEMBL32688124 | 0.86 | ACMSD (0.42) | ACMSDKMT2AMEN1POLBADORA1 | |
| SCHEMBL32688364 | 0.86 | KMT2A (0.51) | KMT2AMEN1POLBNR1H4ALDH1A1 | |
| SCHEMBL32688306 | 0.85 | KMT2A (0.59) | ACMSDKMT2AMEN1POLBADORA1 | |
| SCHEMBL20350857 | 0.84 | ACMSD (0.56) | ACMSDKMT2AMEN1POLBADORA1 | |
| SCHEMBL20339967 | 0.84 | ACMSD (0.58) | ACMSDKMT2AMEN1POLBADORA1 | |
| SCHEMBL32688277 | 0.83 | KMT2A (0.52) | KMT2AMEN1POLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | ACMSD 142/4885KMT2A 3400/4885MEN1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.